Kailera Therapeutics (KLRA) Stock Forecast & Price Target
Score
Kailera Therapeutics, Inc. price target
| KLRA | |
|---|---|
| Low | $36.00 |
| Average | $42.00 |
| High | $48.00 |
| Upside vs current price | +216.5% |
The average target of $42.00 is +216.5% versus the current KLRA price of $13.27.
Kailera Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
7 analysts cover KLRA.
Kailera Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Kailera Therapeutics, Inc. keeps 2026 EPS $-3.92, 2027 EPS $-3.86, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-3.92 | — |
| 2027 | $-3.86 | — |
Is Kailera Therapeutics, Inc. a buy or sell?
Of the 7 analysts covering Kailera Therapeutics, Inc., 7 rate it a buy (1 strong buy and 6 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The KLRA consensus label is Buy, beside 7 buy-side ratings and 0 sell-side ratings.
The average target of $42.00 implies +216.5% versus the current price of $13.27.
the Kailera Therapeutics, Inc. closes with 7 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Kailera Therapeutics, Inc. forecast
Between the KLRA low of $36.00 and the high of $48.00, the average target is $42.00.
From today's $13.27 print, the KLRA average target is +216.5% away.
Most of the KLRA coverage agrees: 7 of 7 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Earnings estimates for KLRA are rising: 2026 $-3.92, then 2027 $-3.86.
KLRA coverage is thin at 7 analysts, and one revision moves the average.
Kailera Therapeutics, Inc. forecast questions
What is the KLRA price target?
The published range for KLRA is $36.00 to $48.00, with an average of $42.00. That average is +216.5% versus the current price of $13.27.
Is Kailera Therapeutics, Inc. a buy or sell?
Of the 7 analysts covering Kailera Therapeutics, Inc., 7 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for KLRA is 7 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Kailera Therapeutics, Inc.?
Analyst EPS estimates for Kailera Therapeutics, Inc.: 2026 $-3.92, 2027 $-3.86.
What is the revenue estimate for Kailera Therapeutics, Inc.?
No revenue estimate with at least 3 analysts is on file for Kailera Therapeutics, Inc..
How many analysts cover KLRA?
7 analysts cover KLRA. Their consensus on KLRA is Buy, across those 7.